| Disease Field | Pipeline Code | Target/Mechanism of Action | Indications | Clinical Region | Preclinical | IND | Phase I | Phase II | Phase III | NDA |
|---|---|---|---|---|---|---|---|---|---|---|
| Autoimmune Diseases/ Inflammatory Diseases |
Mufemilast | PDE4B/ PDE4 |
Ps | China | ||||||
| BD | China | |||||||||
| Global | ||||||||||
| PsA | China | |||||||||
| AS | China | |||||||||
| AD | China | |||||||||
| UC | China | |||||||||
| COPD | China | |||||||||
| CD | China | |||||||||
| Hemay007 | TNF-α | UC | China | |||||||
| RA | China | |||||||||
| Hemay808 | IgE/PDE4 | AD | China | |||||||
| Cancer | Hemay022 | EGFR/HER2 | Metastatic breast cancer |
China | ||||||
| Hemay181 | β-GU | Solid tumor | China | |||||||
| Global | ||||||||||
| Hemay183 | Not disclosed | Solid tumor | / | |||||||
| Hemay5087 | Not disclosed | Solid tumor | / | |||||||
